News After FDA says no, Bayer bags EU nod for twice-yearly Eylea Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.
R&D Looking to early-stage companies for innovation, with Juerge... In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
News Bayer CEO confident firm can cope with Xarelto hit Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.
News Bayer CEO warns of tough 2025 as turnaround plan beds in Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.
News FDA approves first generics of anticoagulant Xarelto The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.